A patent lawsuit filed by Solos Technology against Meta Platforms, Oakley, and EssilorLuxottica targets core smart glasses technology, posing significant risks to Meta's wearables strategy and valuation.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
InterDigital (NASDAQ: IDCC) has laid out an ambitious financial roadmap for fiscal year 2026, forecasting revenues up to $775 million. The outlook is supported by a newly inked licensing agreement with LG Electronics and a key smartphone renewal, signaling strong momentum in its patent portfolio.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
Merck & Co. shares have delivered impressive multi-year returns, climbing over 80% in the past five years. Yet, a deep dive into its valuation metrics suggests the market may still be underestimating the pharmaceutical leader's intrinsic value, presenting a potential opportunity for investors.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
As Merck prepares to release its fourth-quarter results, investors are watching to see if the pharmaceutical leader can maintain its track record of exceeding expectations amid a slowing growth outlook.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
The U.S. Air Force Research Laboratory has awarded Palladyne AI a contract for its HANGTIME project, marking a significant expansion of the company's autonomous swarm software from ground and air assets into the space domain. The deal validates the company's core technology but comes as investors weigh its growth potential against ongoing financial challenges.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.
Spotify and major record labels have filed a staggering $13 trillion lawsuit against Anna's Archive, alleging the platform facilitated the theft of metadata and audio files representing nearly all commercial recordings. The case raises profound questions about digital piracy and copyright enforcement in the streaming era.
Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.
Semiconductor security firm SEALSQ deepens its investment in France, now employing around 200 specialists across its Toulouse, Aix-en-Provence, and Grenoble offices, positioning the country as a core R&D center for its post-quantum cryptography and secure chip technologies.
